EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Atezolizumab and bevacizumab for non‐resectable or metastatic combined hepatocellular‐cholangiocarcinoma: A multicentric retrospective study

Elia Gigante iD, Mohamed Bouattour iD, José Ursic Bedoya iD, Hélène Regnault, Marianne Ziol, Eric Assenat, Valérie Paradis, Julien Calderaro, Nathalie Ganne-Carrié, Karine Bouhier-Leporrier, Giuliana Amaddeo, Jean Charles Nault iD

United European Gastroenterology Journal · 2024-05 · 12 (4) · 429-439

DOI: 10.1002/ueg2.12503 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift United European Gastroenterology Journal, online erschienen am 07.12.2023. Verfasst von Elia Gigante und 11 weiteren Autor:innen. Beteiligte Einrichtung: Université de Reims Champagne-Ardenne, CHU Reims, Service d'Hépato-Gastroentérologie et de Cancérologie digestive, Reims, France. Hauptthemen laut MEDLINE: Bevacizumab, Antibodies, Monoclonal, Humanized, Liver Neoplasms, Carcinoma, Hepatocellular. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Backgrounds The efficacy of atezolizumab/bevacizumab has never been reported in patients with metastatic/unresectable combined hepatocellular‐cholangiocarcinoma (cHCC‐CCA). Patients and Methods We retrospectively included patients with a histological diagnosis of unresectable/metastatic cHCC‐CCA and treated with atezolizumab/bevacizumab (2020–2022) in 7 centers. Clinical and radiological features were collected at the beginning of atezolizumab/bevacizumab. We reported the radiological response using RECIST criteria, overall survival (OS) and progression‐free survival (PFS).

Results

Sixteen patients with cHCC‐CCA were included and were predominantly male (75%) with advanced fibrosis/cirrhosis (69%). Nine patients received atezolizumab/bevacizumab as a first‐line systemic treatment, 5 as a second line, 1 as a third line and 1 as a fifth line. Severe digestive bleeding occurred in 2 patients. Among the 9 patients treated in the first line, 4 experienced radiological progression, 3 partial response and 1 had stable disease. Patients treated with atezolizumab/bevacizumab in the first line had a median OS of 13 months and a median PFS of 3 months. Among the 7 patients receiving atezolizumab/bevacizumab as a second line or more, 4 patients harbored a stable disease, 2 a partial response, and 1 a progressive disease.

Conclusions

The combination of atezolizumab and bevacizumab showed signs of anti‐tumor efficacy in patients with unresectable/metastatic cHCC‐CCA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BevacizumabAntibodies, Monoclonal, HumanizedLiver NeoplasmsCarcinoma, HepatocellularCholangiocarcinomaAntineoplastic Combined Chemotherapy ProtocolsHumansMaleRetrospective StudiesFemaleMiddle AgedAgedBile Duct NeoplasmsProgression-Free SurvivalTreatment OutcomeAdult

Stichwörter der Autor:innen

CCAHCCadvancedatezolizumabbevacizumabcholangiocarcinomacombined hepatocellular‐cholangiocarcinomahepatocellular carcinomaimmunotherapysystemic treatment

Substanzen

BevacizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Université de Reims Champagne-Ardenne, CHU Reims, Service d'Hépato-Gastroentérologie et de Cancérologie digestive, Reims, France.
  • Unité Fonctionnelle Oncologie Hépatique, Hôpital Beaujon, AP-HP, Clichy, France.
  • Department of Hepatogastroenterology, Hepatology and Liver Transplantation Unit, Saint Eloi Hospital, Institut de Génétique Moléculaire de Montpellier, University of Montpellier, CNRS, Montpellier, France.
  • University of Montpellier, Montpellier, France.
  • Service d'hépatologie, Hôpital Mondor, AP-HP, Créteil, France.
  • Service d'Anatomo-Pathologie, Hôpital Avicenne, AP-HP, Bobigny, France.

ORCID-Profile: Elia Gigante, Mohamed Bouattour, José Ursic Bedoya, Jean Charles Nault

Zitieren

APA

Gigante, E., Bouattour, M., Bedoya, J. U., Regnault, H., Ziol, M., Assenat, E., Paradis, V., Calderaro, J., Ganne-Carrié, N., Bouhier-Leporrier, K., Amaddeo, G., & Nault, J. C. (2024). Atezolizumab and bevacizumab for non‐resectable or metastatic combined hepatocellular‐cholangiocarcinoma: A multicentric retrospective study. United European Gastroenterology Journal, 12(4), 429-439. https://doi.org/10.1002/ueg2.12503

Vancouver

Gigante E, Bouattour M, Bedoya JU, Regnault H, Ziol M, Assenat E, et al. Atezolizumab and bevacizumab for non‐resectable or metastatic combined hepatocellular‐cholangiocarcinoma: A multicentric retrospective study. United European Gastroenterology Journal. 2024;12(4):429-439. doi:10.1002/ueg2.12503

BibTeX
@article{Gigante2024,
  author = {Gigante, Elia and Bouattour, Mohamed and Bedoya, José Ursic and Regnault, Hélène and Ziol, Marianne and Assenat, Eric and Paradis, Valérie and Calderaro, Julien and Ganne-Carrié, Nathalie and Bouhier-Leporrier, Karine and Amaddeo, Giuliana and Nault, Jean Charles},
  title = {Atezolizumab and bevacizumab for non‐resectable or metastatic combined hepatocellular‐cholangiocarcinoma: A multicentric retrospective study},
  journal = {United European Gastroenterology Journal},
  year = {2024},
  volume = {12},
  number = {4},
  pages = {429--439},
  doi = {10.1002/ueg2.12503}
}
Kostenlos starten →